Study: NCT06704724

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07985045
Description: KRAS inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07985045
Description: KRAS inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07985045
Description: KRAS inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07985045
Description: KRAS inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07985045
Description: KRAS inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07985045
Description: KRAS inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07985045
Description: KRAS inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07985045
Description: KRAS inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07985045
Description: KRAS inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07985045
Description: KRAS inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07985045
Description: KRAS inhibitor

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Chemotherapy (antimetabolite)

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Taxane-type Chemotherapy

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Monoclonal Antibody (EGFR Inhibitor)

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Part of FOLFOX chemotherapy regimen~cytotoxic chemotherapy (antimetabolite and pyrimidine analog)

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Part of FOLFOX Chemotherapy Regimen~platinum based compound (alkylating agent)

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Part of FOLFOX chemotherapy regimen~Folic Acid Analog

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: VEG-F inhibitor

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: immune checkpoint inhibitor (PD-1 inhibitor

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: immune checkpoint inhibitor (PD-1 inhibitor

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Sasanlimab
Description: immune checkpoint inhibitor (PD-1 inhibitor)

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: Can be used in Platinum-based Chemotherapy regimen~Antimetabolite

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Can be used as part of Platinum-based chemotherapy regimen~Platinum-based antineoplastic (alkylating agent)

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Can be used in Platinum-based chemotherapy regimen~Taxane